Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Comment by 40Baggson Apr 14, 2019 1:30pm
255 Views
Post# 29624801

RE:LHS & CC Pharma In Results > Email from IR

RE:LHS & CC Pharma In Results > Email from IRBased off the previous quarter results, this is what could be expected.. 3409KG was sold Q2.. consisting of 1965KG REC (6 weeks @$6.32/g) and 1444KG ($7.51/g) MED.

Conservatively we could assume that medical prices are decreased to $6.32/g to match rec prices and in 12 weeks of rec sales, the company sells 1965KG x 2 = 3930KG, while selling ~1440KG med. That would result in a total of 5370KG @$6.32/g = ~34M less 12% = ~30M. 

Information regarding Q2 from https://www.prnewswire.com/news-releases/aphria-records-63-net-revenue-growth-in-fiscal-2019-second-quarter-announces-executive-team-transition-300776793.html

Also worth noting from the above news release: Net income for the second quarter of 2019 was $54.8 million or $0.22 per share, compared to $21.2 million or $0.09 per share in the previous period, and $6.5 million or $0.05 per share for the same period last year. The increase in net income relates to gains on our long-term investment portfolio, primarily our divestitures of positions in Hiku Brands and Liberty Health Sciences.

It appears the 47M liquidation of the LHS note recievable will show up as cash/receivable and not a gain. A positive EPS will depend on the SGA costs and non-operating gains/losses, as well as the net income from 7 weeks of CC pharma. April 15th results + guidance will be interesting. BOD, Diamond, Extraction Centre updates would be beneficial.


gottahunch wrote: Thanks to the person who brought to my attention that people are still spreading incorrect rumours and this time about CC Pharma. I wouldn't have seen this as this person is on my ignore but someone sent it to me.

Below is the full email I received from Investor Relations. I believe I'm not the only member of Stockhouse that checked this out and received such an email. I will call out liars when I see them, these types of people are the worst of the worst individuals. Lying and spreading false info to create fear to try to have your own personal gain is sick and if what you say here really matters to the greater market anyway.

Karma's a b!tch boys and it will bite you in the a$$.  You know how karma really works - you want to make yourself rich, help make others rich.

Put these people  on ignore.

Email received March 22nd @ 1:04 PM EST.

RE: [EXTERNAL] Next q financials and LHS

 
Hi
 
The divestiture of all interest in Liberty Health will be included on the upcoming Q3 2019 earnings reports.  
 
CC Pharma’s financial contributions from the effective date of the acquisition January 9th, 2019 will be recognized in the 2019 Q3 earnings report.
 
Our Q3 2019 earnings release date is targeted for April 15th, 2019. Our official date and time of release, together with any conference call details, will be communicated in advance via a press release.
 
Thanks,
 
Joel Pierce
Investor Relations Administrator
 



Bullboard Posts